The LDLR-Mediated Reverse Cholesterol Transport Modulation strategy proposes that CNS drug delivery can be enhanced by hijacking the LDLR-dependent reverse cholesterol transport pathway through engineered high-density lipoprotein (HDL) nanocarriers. This approach leverages the bidirectional nature of LDLR-mediated cholesterol trafficking, where apolipoprotein A-I (APOAI) and HDL particles facilitate cholesterol efflux from brain tissue back to peripheral circulation. The strategy involves engineering biomimetic HDL nanoparticles loaded with therapeutic payloads and surface-functionalized with APOAI or synthetic LDLR-binding peptides that exhibit enhanced affinity for LDLR compared to native lipoproteins. Unlike the endosomal escape mechanism of the parent hypothesis, this approach exploits the natural reverse transcytotic pathway where LDLR-bound HDL complexes undergo retrograde transport from the brain parenchymal side to the blood side of the blood-brain barrier.

The LDLR-Mediated Reverse Cholesterol Transport Modulation strategy proposes that CNS drug delivery can be enhanced by hijacking the LDLR-dependent reverse cholesterol transport pathway through engineered high-density lipoprotein (HDL) nanocarriers. This approach leverages the bidirectional nature of LDLR-mediated cholesterol trafficking, where apolipoprotein A-I (APOAI) and HDL particles facilitate cholesterol efflux from brain tissue back to peripheral circulation. The strategy involves engineering biomimetic HDL nanoparticles loaded with therapeutic payloads and surface-functionalized with APOAI or synthetic LDLR-binding peptides that exhibit enhanced affinity for LDLR compared to native lipoproteins. Unlike the endosomal escape mechanism of the parent hypothesis, this approach exploits the natural reverse transcytotic pathway where LDLR-bound HDL complexes undergo retrograde transport from the brain parenchymal side to the blood side of the blood-brain barrier. The critical innovation lies in creating 'Trojan horse' HDL particles that appear as cholesterol-efflux substrates to brain endothelial cells but carry therapeutic cargo in their lipid core or conjugated to their surface apolipoproteins. By pharmacologically upregulating LDLR expression through PCSK9 inhibitors or HMG-CoA reductase modulators, the cholesterol transport machinery can be amplified to increase transcytotic flux. This reverse-direction hijacking transforms the brain's natural cholesterol clearance mechanism into a drug delivery conduit, potentially achieving sustained CNS therapeutic concentrations while following physiological transport kinetics. The approach is particularly promising for lipophilic drugs, nucleic acid therapeutics, and protein drugs that can be incorporated into or conjugated to HDL particles, offering applications in treating neuroinflammation, neurodegeneration, and brain cancers where traditional delivery methods fail to achieve therapeutic CNS concentrations.